Commentary on “Methodological recommendations for cognition trials in bipolar disorder by the International Society for Bipolar Disorders Targeting Cognition Task Force”

Rheenen, Tamsyn E Van

doi:10.1111/bdi.12577

Cited by 1 publication

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6 These guidelines, which address diagnostic (subtypes and comorbidities), clinical (symptoms, medications), and measurement issues (cognitive and functional outcome measures), were recently expanded in the International Society of Bipolar Disorders Targeting Cognition Taskforce methodological recommendations paper and associated commentaries. 14,17,18 Notable suggestions from these papers involve specific guidance regarding the use of certain classes of pharmacological agents for clinical trial design, and the following other recommendations:…”

Section: The Use Of the Matrics Consensus Cognitivementioning

confidence: 99%

Conducting clinical studies targeting cognition in psychiatry: guiding principles and design

et al. 2018

View full text Add to dashboard Cite

Cognitive dysfunction is common in many psychiatric disorders. While it has long been described as a core feature in schizophrenia, more recent data suggest qualitatively similar impairments in patients with bipolar disorder and major depressive disorder. There is compelling evidence to suggest that cognitive impairment contributes directly to functional disability and reduced quality of like across these disorders. As current treatments focus heavily on “primary” symptoms of mood and psychosis, the standard of care typically leaves cognitive deficits unmanaged. With this in mind, the field has recently begun to consider intervening directly on this important symptom domain, with several ongoing trials in schizophrenia. Fewer studies have targeted cognition in bipolar disorder and still fewer in MDD. With progress toward considering this domain as a target for treatment comes the need for consensus guidelines and methodological recommendations on cognitive trial design. In this manuscript, we first summarize the work conducted to date in this area for schizophrenia and for bipolar disorder. We then begin to address these same issues in MDD and emphasize the need for additional work in this area.

show abstract